B cell elimination in systemic lupus erythematosus

Furtado, João M; Isenberg, David

doi:10.1016/j.clim.2012.11.006

Cited by 37 publications

(25 citation statements)

References 58 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Thus, at variance with the numerous offlabel trials that reported very encouraging results [20,27,28 ], the two randomized placebo-controlled studies did not meet their endpoints [29,30]. A critical review of the data available highlights different levels of heterogeneity between studies which may explain the discrepancy [28 ].…”

Section: The Different Facets Of B Lymphocyte Targetingmentioning

confidence: 96%

“…criteria for response and flares and their assessment) [28 ]. This latter issue is indeed a major pitfall due to the various existing scores to grade SLE severity and the need for good clinical experience to apply them wisely [28 ]. The fact remains that in the off-label studies a better therapeutic efficacy was generally correlated with the degree of B cell depletion achieved and that a good clinical response rate also was accompanied by improvement in laboratory parameters.…”

Section: The Different Facets Of B Lymphocyte Targetingmentioning

confidence: 97%

“…These include differences in the clinical profile of patients included, their ethnicity, the cumulative dose of rituximab administered, the duration of follow-up, the degree of B cell depletion achieved and last but not least the choice of end points (i.e. criteria for response and flares and their assessment) [28 ]. This latter issue is indeed a major pitfall due to the various existing scores to grade SLE severity and the need for good clinical experience to apply them wisely [28 ].…”

Section: The Different Facets Of B Lymphocyte Targetingmentioning

confidence: 99%

See 2 more Smart Citations

Biotherapies targeting T and B cells: from immune suppression to immune tolerance

Chatenoud

2015

Current Opinion in Pharmacology

View full text Add to dashboard Cite

Section: The Different Facets Of B Lymphocyte Targetingmentioning

confidence: 96%

Section: The Different Facets Of B Lymphocyte Targetingmentioning

confidence: 97%

Section: The Different Facets Of B Lymphocyte Targetingmentioning

confidence: 99%

See 1 more Smart Citation

Biotherapies targeting T and B cells: from immune suppression to immune tolerance

Chatenoud

2015

Current Opinion in Pharmacology

View full text Add to dashboard Cite

“…There are many reports of an increase in anti-dsDNA (and antinucleosome) antibodies rising concomitantly with, or in advance of, the overt development of LN [67], and the recent use of rituximab as a first-line agent in LN was in many cases associated with improvement both in the nephritis and in the level of anti dsDNA antibodies [68].…”

Section: Antibody Profilementioning

confidence: 98%

Risk factors for renal disease in systemic lupus erythematosus and their clinical implications

Ntatsaki

Isenberg

2015

Expert Review of Clinical Immunology

View full text Add to dashboard Cite

Lupus nephritis is one of the most common severe manifestations of systemic lupus erythematosus and is associated with significant morbidity and mortality. Genetic, ethnic and hormonal factors may influence the presence and severity of renal involvement and therefore affect the outcome and overall prognosis of patients. In this review, we will discuss the association of known lupus risk factors in developing renal disease and explore the recent literature to identify potential risk factors and their clinical implications in terms of diagnostic vigilance, management and prognosis.

show abstract

“…Targeting CD20, a cell surface molecule expressed mainly on mature B lymphocytes, by rituximab has been proven being of great benefit in many hematological and immune-mediated disorders [56,57]. Rituximab has been used in the treatment of many autoimmune diseases including rheumatoid arthritis, systemic lupus erythematosus, dermatomyositis, autoimmune hemolytic anemia and others [58].…”

Section: B Lymphocytes and Inflammatory Bowel Diseasesmentioning

confidence: 99%

Targeting T and B Lymphocytes in Inflammatory Bowel Diseases: Lessons from Clinical Trials

Gerner

Moschen

Tilg

2013

Dig Dis

View full text Add to dashboard Cite

Both innate and adaptive immunity play an important role in the pathogenesis of inflammatory bowel diseases (IBDs). There is strong evidence that especially activated T cells initiate and perpetuate inflammation and tissue destruction. The increased numbers of CD4⁺ T cells in the intestinal wall of IBD patients may be explained by enhanced influx/activation and decreased apoptosis of these cells. Several studies have demonstrated that the gut-homing receptors CCR9 and α4β7 are selectively induced on T cells during their priming in intestinal inflamed sites. Whereas targeting of activated CD4⁺ T cells by specific antibody strategies or neutralization of key T-cell cytokines such as IL-2 or IFN-γ has not been effective in human IBD, blocking migration of activated leukocytes, e.g. T cells into the inflamed tissue by specific antibodies such as vedolizumab, seems highly effective. Recently it could also been demonstrated that administration of antigen-specific regulatory T cells to patients with refractory Crohn's disease was not only well tolerated but showed promising results. The role of B cells in human IBD is less clear. B-cell depletion has so far only been studied in ulcerative colitis where rituximab (anti-CD20) therapy failed. Therefore, although the therapeutic targeting of ‘inflammatory' T and B cells was not successful in IBD, especially T cells remain key players in IBD. Targeting either T-cell migration or the use of regulatory T cells appears as the most promising ‘T-cell-directed' therapies in the future.

show abstract

B cell elimination in systemic lupus erythematosus

Cited by 37 publications

References 58 publications

Biotherapies targeting T and B cells: from immune suppression to immune tolerance

Biotherapies targeting T and B cells: from immune suppression to immune tolerance

Risk factors for renal disease in systemic lupus erythematosus and their clinical implications

Targeting T and B Lymphocytes in Inflammatory Bowel Diseases: Lessons from Clinical Trials

Contact Info

Product

Resources

About